metoprolol has been researched along with Alloxan Diabetes in 18 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 7.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| " The diabetic and control non-diabetic rats were assigned randomly to receive no anti-hypertension treatment, or to be treated with the angiotensin II receptor blocker (ARB), valsartan (40 mg/kg/d) or the beta-blocker, metoprolol (50 mg/kg/day)." | 3.78 | Aquaporin changes during diabetic retinopathy in rats are accelerated by systemic hypertension and are linked to the renin-angiotensin system. ( Fan, J; Hoffman, MR; Qin, Y; Ren, H; Xu, G; Zhang, M, 2012) |
| "We compared the effects of the angiotensin-converting enzyme inhibitor enalapril and a conventional antihypertensive regimen (hydralazine and metoprolol) on kidney function, albuminuria, and glomerular ultrastructure in hypertensive diabetic and nondiabetic rats." | 3.68 | Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. ( Allen, TJ; Clarke, BE; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Papazoglou, D, 1990) |
| "Metoprolol is a selective β1-adrenergic receptor antagonist metabolized by hepatic cytochrome P450s (CYPs)." | 1.39 | Faster non-renal clearance of metoprolol in streptozotocin-induced diabetes mellitus rats. ( Kang, HE; Lee, BK; Lee, I; Lee, U, 2013) |
| "Metoprolol can increase the VFT and decrease the excitation threshold of the ischemic myocardium in diabetic rats." | 1.37 | [Effects of metoprolol on electrophysiology of ischemic and anoxic myocardium in diabetic rats]. ( Chen, JM; He, L; Jin, HF; Shen, FR; Sun, GJ; Wang, ZJ; Zeng, WP; Zhong, C, 2011) |
| "Metoprolol prevented the increase in PGC1alpha occupation of the CPT-1B promoter region observed in the diabetic heart without affecting PPAR-alpha occupation." | 1.35 | Metoprolol represses PGC1alpha-mediated carnitine palmitoyltransferase-1B expression in the diabetic heart. ( Allard, MF; Dhillon, P; McNeill, JH; Parsons, H; Sharma, V, 2009) |
| "Metoprolol treatment produced a slight but significant reduction in serum glucose levels with elevation in serum insulin levels, while atenolol produced a slight increase in glucose levels but no effect on insulin levels." | 1.34 | Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats. ( Bhadada, SV; Goyal, RK, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 2 |
| Li, QQ | 2 |
| Huang, CK | 2 |
| Dong, YY | 2 |
| Lang, LP | 2 |
| Sun, W | 2 |
| Qian, JC | 2 |
| Zhang, XD | 2 |
| Lee, U | 1 |
| Lee, I | 1 |
| Lee, BK | 1 |
| Kang, HE | 1 |
| Patel, BM | 1 |
| Bhadada, SV | 2 |
| Sharma, V | 4 |
| Parsons, H | 3 |
| Allard, MF | 4 |
| McNeill, JH | 4 |
| Dhillon, P | 2 |
| Mason, RP | 1 |
| Kubant, R | 1 |
| Jacob, RF | 1 |
| Malinski, P | 1 |
| Huang, X | 1 |
| Louka, FR | 1 |
| Borowiec, J | 1 |
| Mizuno, Y | 1 |
| Malinski, T | 1 |
| Sharma, A | 1 |
| Saran, V | 1 |
| Bernatchez, PN | 1 |
| Jin, HF | 1 |
| Zeng, WP | 1 |
| Shen, FR | 1 |
| Wang, ZJ | 1 |
| He, L | 1 |
| Sun, GJ | 1 |
| Chen, JM | 1 |
| Zhong, C | 1 |
| Qin, Y | 1 |
| Ren, H | 1 |
| Hoffman, MR | 1 |
| Fan, J | 1 |
| Zhang, M | 1 |
| Xu, G | 1 |
| Dorenkamp, M | 1 |
| Riad, A | 1 |
| Stiehl, S | 1 |
| Spillmann, F | 1 |
| Westermann, D | 1 |
| Du, J | 1 |
| Pauschinger, M | 1 |
| Noutsias, M | 1 |
| Adams, V | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Fiordaliso, F | 1 |
| De Angelis, N | 1 |
| Bai, A | 1 |
| Cuccovillo, I | 1 |
| Salio, M | 1 |
| Serra, DM | 1 |
| Bianchi, R | 1 |
| Razzetti, R | 1 |
| Latini, R | 1 |
| Masson, S | 1 |
| Goyal, RK | 1 |
| Wambolt, R | 1 |
| Brownsey, R | 1 |
| Iwai, T | 1 |
| Irlbeck, M | 1 |
| Zimmer, HG | 1 |
| Olbrich, A | 1 |
| Salameh, A | 1 |
| Roesen, P | 1 |
| Dhein, S | 1 |
| Teschner, M | 1 |
| Schaefer, RM | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| O'Brien, RC | 1 |
| Papazoglou, D | 1 |
| Clarke, BE | 1 |
| Jerums, G | 1 |
| Doyle, AE | 1 |
| Baba, T | 1 |
| Sawicki, PT | 1 |
1 review available for metoprolol and Alloxan Diabetes
| Article | Year |
|---|---|
[Nephropathy in type 1 diabetes mellitus. Current experimental and clinical aspects].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Experimental; Dia | 1992 |
17 other studies available for metoprolol and Alloxan Diabetes
| Article | Year |
|---|---|
Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS/MS method.
Topics: Acetaminophen; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P- | 2023 |
Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS/MS method.
Topics: Acetaminophen; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P- | 2023 |
Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS/MS method.
Topics: Acetaminophen; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P- | 2023 |
Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS/MS method.
Topics: Acetaminophen; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P- | 2023 |
Faster non-renal clearance of metoprolol in streptozotocin-induced diabetes mellitus rats.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Animals; Diabetes Mellitus, Experiment | 2013 |
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Disease | 2014 |
Metoprolol increases the expression of beta(3)-adrenoceptors in the diabetic heart: effects on nitric oxide signaling and forkhead transcription factor-3.
Topics: Adrenergic beta-Antagonists; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP | 2008 |
Metoprolol represses PGC1alpha-mediated carnitine palmitoyltransferase-1B expression in the diabetic heart.
Topics: Adrenergic beta-Antagonists; Animals; Carnitine O-Palmitoyltransferase; Diabetes Mellitus, Experimen | 2009 |
Loss of arterial and renal nitric oxide bioavailability in hypertensive rats with diabetes: effect of beta-blockers.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arteries; Benzopyrans; Blood Glucose; | 2009 |
β-receptor antagonist treatment prevents activation of cell death signaling in the diabetic heart independent of its metabolic actions.
Topics: Adrenergic beta-Antagonists; Animals; bcl-Associated Death Protein; Caspase 3; Caveolins; Cell Death | 2011 |
[Effects of metoprolol on electrophysiology of ischemic and anoxic myocardium in diabetic rats].
Topics: Animals; Diabetes Mellitus, Experimental; Heart; Male; Metoprolol; Myocardial Ischemia; Nerve Growth | 2011 |
Aquaporin changes during diabetic retinopathy in rats are accelerated by systemic hypertension and are linked to the renin-angiotensin system.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporins | 2012 |
Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2005 |
Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes C | 2007 |
Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Glucose; Blood Pressure; Cardiomegaly; Cardiov | 2007 |
Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat.
Topics: Acetyl-CoA Carboxylase; Adenosine Triphosphate; Adrenergic beta-Antagonists; AMP-Activated Protein K | 2008 |
Measurement of left ventricular maximal isovolumetric pressure in rats: effects of antihypertensive drugs and diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Animals | 1998 |
Different effects of the beta-adrenoceptor antagonists celiprolol and metoprolol on vascular structure and function in long-term type I diabetic rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Chemical Analysis; Blood Vessels; Celiprolol; Cells, Cul | 1999 |
Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
Topics: Administration, Oral; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Melli | 1990 |
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat: are these effects specific for enalapril?
Topics: Albuminuria; Animals; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic N | 1989 |